Aim: The study aimed to evaluate the maternal and fetal outcomes of corticosteroid administration in the late preterm period, focusing on its effects on neonatal respiratory complications and overall safety. Materials and Methods: This prospective observational study included 100 pregnant women between 34+0 and 36+6 weeks of gestation at risk of preterm delivery. Participants were divided into two groups: the Corticosteroid Group (n=50), who received two doses of 12 mg betamethasone intramuscularly 24 hours apart, and the Control Group (n=50), who received routine obstetric care. Comprehensive data on maternal history, blood pressure, signs of infection, and adverse reactions were collected. Neonatal outcomes, including birth weight, Apgar scores, respiratory distress syndrome (RDS), and NICU admission, were documented. Statistical analysis was performed using SPSS version 25.0, with p-values <0.05 considered significant. Results: The mean age of participants was comparable between groups. Maternal outcomes showed a higher but not significant rate of hyperglycemia in the Corticosteroid Group (16% vs. 6%, p=0.12). The incidence of RDS was significantly lower in the Corticosteroid Group (12% vs. 28%, p=0.04), and NICU stays were shorter (3.5 days vs. 4.2 days, p=0.03). Apgar scores at 1 and 5 minutes were significantly higher in the Corticosteroid Group (p=0.02 and p=0.01, respectively). Other neonatal morbidities, such as hypoglycemia and jaundice, showed no significant differences. Conclusion: Corticosteroid administration in the late preterm period significantly reduces neonatal respiratory complications and improves Apgar scores, with an acceptable maternal safety profile. These findings support the use of corticosteroids in managing late preterm births, emphasizing individualized patient care.